Progress of tumor marker research in Nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is a prevalent tumour in southernChina and southeast Asia, particularly in the Cantonese population, where its incidence has remained high for decades.This cancer is an Epstein-Barr virus-associated malignancy with a remarkable racial and geographical distribution. It is highly prevalent in southern Asia where the disease occurs at a prevalence about a 100-fold higher compared with other populations not at risk. We still see patients recur after primary treatment with radiotherapy or chemo-irradiation. Management of nasopharyngeal carcinoma remains one of the biggest clinical challenges. There have been break throughs in early detection, diagnosis, multi-modality treatment and also disease monitoring for NPC. Systemic treatment has been crucial to the management of locally advanced or metastatic NPC. With the advent of molecular targeted therapy and personalized medicine, novel therapies based on molecular targets of NPC have become the focus of research and development over the last decade，The etiology of NPC is thought to be associated with a complex interaction of genetic, viral,environmental and dietary factors.Thanks to the advancements in genomics, proteomics and bioinformatics in recent decades, more understanding of the disease etiology,carcinogenesis and progression has been gained. Research into these components may unravel the pathways in NPC development and potentially decipher the molecular characteristics of the malignancy in recent years, the attention to the study of tumor markers associated with the NPC, this paper summarizes the research progress of the NPC in recent years, a variety of related research progress of tumor markers and its early diagnosis and curative effect evaluation to the NPC, treatment and prognosis of great significance.
Kontos CK, Fendri A, Khabir A, Mokdad-Gargouri R, Scorilas A. Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer. 2013,13:293.
Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010, 21(5):471-477.
Perri F, Bosso D, Buonerba C, Lorenzo GD, Scarpati GD. Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. World J Clin Oncol. 2011, 2(12):377-383.
Tang MZ, Cai YL, Zheng YM, Zeng Y. Association between human leukocyte antigen and nasopharyngeal-carcinoma.Yi Chuan. 2012, 34(12):1505-1512.
Li X1, Fasano R, Wang E, Yao KT, Marincola FM. HLA associations with nasopharyngeal carcinoma. Curr Mol Med. 2009, 9(6):751-765.
Tiwawech D1, Srivatanakul P, Karalak A, Ishida T. Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett. 2006, 241(1):135-141.
Old LJ, Boyse EA, Oettgen HF, Harven ED, Geering G, Williamson B, Clifford P. Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 1966, 56(6):1699-1704.
Forte E, Luftig MA. The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. Microbes Infect. 2011, 13(14-15):1156-1167.
Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L, Tao Y, Cao Y. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res. 2013, 32(1):90.
Luo YL, Chen H, Peng SG, Lin JH, Huang PY. Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi. 2013, 93(44):3516-3519.
Chan KC, Lo YM. Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA. Methods Mol Biol. 2006, 336:111-121.
Gou Y, Sun C, Hu L, He J, Zhang C, Feng Y, Zhang P, Kong X, Xiao L, Li Y. Correlation between DNA damage and EB virus infection in nasopharyngeal
carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014, 30(2):184-187.
Tarbouriech N, Ruggiero F, de Turenne-Tessier M, Ooka T, Burmeister WP. Structure of the Epstein-Barr virus oncogene BARF1. J Mol Biol. 2006, 359(3):667-678.
Chang MS, Kim DH, Roh JK, Middeldorp JM, Kim YS, Kim S, Han S, Kim CW, Lee BL, Kim WH, Woo JH. Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-Κb. J Virol. 2013, 87(19):10515-10523.
Houali K, Wang X, Shimizu Y, Djennaoui D, Nicholls J, Fiorini S, Bouguermouh A, Ooka T. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res. 2007, 13(17):4993-5000.
Du C, Yang P, Zhang G, Hong C, Chen J, Dong X. Effect of Arsenic trioxide on EBV LMP1 mediated E-cadherin silencing in nasopharyngeal carcinoma. Head Neck Oncol. 2012, 4:55.
Du C, Wen B, Li D, Lin Y, Zheng Y, Peng X, Hong C, Chen J, Lin W, Hong X, Xie L, Wu M. Downregulation of Epstein-Barr virusencoded latent membrane protein-1 by arsenic trioxide innasopharyngeal carcinoma cells. Tumori. 2006, 92(2):140-148.
Du CW, Wen BG, Li DR, Peng X, Hong CQ, Chen JY, Lin ZZ, Hong X, Lin YC, Xie LX, Wu MY, Zhang H. Arsenic trioxide reduces the invasive and metastatic properties of nasopharyngeal carcinoma cells in vitro. Braz J Med Biol Res. 2006, 39(5):677-685.
Yu PH, Chou SF, Chen CL, Hung H, Lai CY, Yang PM, Jeng YM, Liaw SF, Kuo HH, Hsu HC, Chen JY, Wang WB. Upregulation of endocan by epstein-barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. PLoS One. 2013, 8(12):e82254.
Fotheringham JA, Mazzucca S, Raab-Traub N. Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation.Oncogene. 2010, 29(30):4287-4296.
Li S., Deng Y, Li X, Chen QP, Liao XC, Qin X. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J (Engl). 2010, 123(9):1201-1205.
Wong AM1, Kong KL, Tsang JW, Kwong DL, Guan XY. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs.Cancer. 2012, 118(3):698-710.
Chen YK, Su CT, Ding HJ, Chi KH, Liang JA, Shen YY, Chen LK, Yeh CL, Liao AC, Kao CH. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res. 2006, 26(2B):1471-1477.
Abou-Elhamd KE1, Habib TN. The flow cytometric analysis of premalignant and malignant lesions in head and neck squamous cell carcinoma.Oral Oncol. 2007, 43(4):366-372.
Sun D, Zhang Z, Van do N, Huang G, Ernberg I, Hu L. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol. 2007, 43(1):82-87.
Chen H, Luo YL, Zhang L, Tian LZ, Feng ZT, Liu WL. EA-D p45-IgG as a potential biomarker for nasopharyngeal carcinoma diagnosis. Asian Pac J Cancer Prev. 2013, 14(12):7433-7438.
Tian F, Yip SP, Kwong DL, Lin Z, Yang Z, Wu VW. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol. 2013, 37(5):708-713.
Huang L1, Huang W, Chen Y. Diagnostic value of combined detection of CYFRA21-1 and TSGF in nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005, 19(5):201-202.
Allon AA, Butcher K, Schneider RA, Lotz JC. Structured bilaminar coculture outperforms stem cells and disc cells in a simulated degenerate disc environment. Spine (Phila Pa 1976). 2012, 37(10):813-818.
Zhang Z, Sun D, Hutajulu SH, Nawaz I, Nguyen Van D, Huang G, Haryana SM, Middeldorp JM, Ernberg I, Hu LF. Development of a non-invasive method, multiplex methylation specific PCR (MMSP), for early diagnosis of nasopharyngeal carcinoma. PLoS One. 2012, 7(11):e45908.
Liu H, Zhang L, Niu Z, Zhou M, Peng C, Li X, Deng T, Shi L, Tan Y, Li G. Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. BMC Cancer. 2008, 8:253.
He ML, Luo MX, Lin MC, Kung HF. MicroRNAs: potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma.Biochim Biophys Acta. 2012, 1825(1):1-10.
Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP, MAC-NPC Collaborative Group: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006, 64(1):47-56.
Jeyakumar A, Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. Ear Nose Throat J. 2006, 85(3):168-170.
Anghel I, Anghel AG, Dumitru M, Soreanu CC. Nasopharyngeal carcinoma -- analysis of risk factors and immunological markers. Chirurgia (Bucur). 2012, 107(5):640-645.
Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013, 108(3):370-377.
Xu F, Wen Z, Qiu YZ, Xiao JY, Zhao SP, Guo MH. Tumor-targeted human telomerase reverse transcriptase promoter/tk gene therapy against human nasopharyngeal carcinoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 2010, 30(4):695-699.
Akhtar RS, Geng Y, Klocke BJ, Latham CB, Villunger A, Michalak EM, Strasser A, Carroll SL, Roth KA. BH3-only proapoptotic Bcl-2 family members Noxa and Puma mediate neural precursor cell death. J Neurosci. 2006, 26(27):7257-7264.
Ying X, Zhang R, Wang H, Teng Y. Lentivirus-mediated RNAi knockdown of LMP2A inhibits the growth of nasopharyngeal carcinoma cell line C666-1 in vitro.Gene. 2014, S0378-1119(14):00298-4.
Song Y, Dong MM, Yang HF. Effects of RNA interference targeting four different genes on the growth and proliferation of nasopharyngeal carcinoma CNE-2Z cells. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010, 45(9):751-758.
Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH, Cheng SH, Tsang CM, Tsao SW, Chan AT. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett. 2010, 287(1):23-32.
Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O'Sullivan B, Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011, 71(6):2381-2391.
Zhao L, Li X, Ma J, Zhang N, Wang H. Effects of the inhibition and apoptosis by shRNA mediated survivin gene silencing in xenograft tumor of nasopharyngeal carcinoma cell CNE-2 . Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013, 27(8):420-424.
Chan SY, To KF, Leung SF, Yip WW, Mak MK, Chung GT, Lo KW. 14-3-3 sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma. Oncol Rep. 2010, 24(4):949-955.
Cai MB, Han HQ, Bei JX, Liu CC, Lei JJ, Cui Q, Feng QS, Wang HY, Zhang JX, Liang Y, Chen LZ, Kang TB, Shao JY, Zeng YX. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma. Int J Biol Sci. 2012, 8(6):891-900.
Liao Q, Guo X, Li X, Xiong W, Li X, Yang J, Chen P, Zhang W, Yu H, Tang H, Deng M, Liang F, Wu M, Luo Z, Wang R, Zeng X, Zeng Z, Li G. Prohibitin is an important biomarker for nasopharyngeal carcinoma progression and prognosis. Eur J Cancer Prev. 2013, 22(1):68-76.
Liu Z, Chen J, Luo W, Yang H, Wu A, Zhen Y, Yu X, Wang H, Yao K, Li X, Fang W. Overexpressed DNA-binding protein inhibitor 2 as an unfavorable prognosis factor promotes cell proliferation in nasopharyngeal carcinoma.Acta Biochim Biophys Sin (Shanghai). 2012, 44(6):503-512.
Nie Y, Liu X, Qu S, Song E, Zou H, Gong C. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival.Cancer Sci. 2013, 104(4):458-464.
Cao XJ, Hao JF, Yang XH, Xie P, Liu LP, Yao CP, Xu J. Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol. 2012, 29(1):263-271.
Zheng J, Li J, Xu L, Xie G, Wen Q, Luo J, Li D, Huang D, Fan S. Phosphorylated Mnk1 and eIF4E Are Associated with Lymph Node Metastasis and Poor Prognosis of Nasopharyngeal Carcinoma. PLoS One. 2014, 9(2):e89220.
Li M, Li C, Li D, Xie Y, Shi J, Li G, Guan Y, Li M, Zhang P, Peng F, Xiao Z, Chen Z. Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma.Clin Exp Metastasis. 2012, 29(8):865-877.
Cai MY1, Tong ZT, Zhu W, Wen ZZ, Rao HL, Kong LL, Guan XY, Kung HF, Zeng YX, Xie D. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma.Mol Med. 2011, 17(11-12):1137-4115.
Chang KP, Wu CC, Chen HC, Chen SJ, Peng PH, Tsang NM, Lee LY, Liu SC, Liang Y, Lee YS, Hao SP, Chang YS, Yu JS. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis.Proteomics. 2010, 10(14):2644-2660.
Cho WC. Research progress in SELDI-TOF MS and its clinical applications. Sheng Wu Gong Cheng Xue Bao. 2006, 22(6):871-876.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Asia Press is a professional Science, Technology and Medicine publisher, who owns rapid publication, Peer-Reviewed, Open Access Journals. Asia Press aims to promote “knowledge sharing”. As you know, the main barrier for free “knowledge sharing” is the cost of publishing and transfer. In order to encourage scholars and scientists to the max, and devote whole power to realize the aim of “knowledge sharing” and the benefit of “all” mankind, Asia Press performs a permanent policy of no charge for publication and access, and always open its door for authors worldwide.
© 2013-2017 by the Asia Press. All rights reserved.
© 2013-2017 by the Asia Press. All rights reserved.